Objective: MicroRNAs (miRNAs) have been shown to anticipate great cancer diagnostic potential. We investigated whether plasma miRNAs could discriminate patients with and without colorectal cancer (CRC).
Methods: This study was divided into three phases: (i) Marker discovery using real-time PCR-based miRNA profiling on plasma, corresponding cancerous and adjacent non-cancerous colonic tissues of 5 CRC patients, along with plasma from 5 healthy individuals as controls. (ii) Marker selection and validation by real-time quantitative RT-PCR on a small set of plasma. (iii) Independent validation on a large set of plasma from 90 CRC patients, 20 gastric cancer patients, 20 patients with inflammatory bowel disease (IBD) and 50 healthy controls.
Results: Of the panel of 95 miRNAs analyzed, 5 miRNAs were up-regulated both in plasma and tissue samples. All the 5 miRNAs were validated on the plasma of 25 CRC patients and 20 healthy controls. Both miR-17-3p and miR-92 were significantly elevated in CRC patients (p<0.0005). The plasma levels of these markers were significantly reduced after surgery in 10 CRC patients (p<0.05). Further validation with an independent set of plasma samples (n=180) indicated that miR-92 differentiates CRC from gastric cancer, IBD and normal subjects. This marker yielded a receiver operating characteristic curve area of 88.5%. At a cutoff of 240 (relative expression in comparison to RNU6B snRNA), the sensitivity was 89% and the specificity was 70% in discriminating CRC from control subjects.
Conclusion: MiR-92 is significantly elevated in plasma of CRC patients and can be a potential noninvasive molecular marker for CRC screening.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.